Brian J. Davis

Array ( [id] => 19001936 [patent_doc_number] => 20240066007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => TREATMENTS WITH NIROGACESTAT [patent_app_type] => utility [patent_app_number] => 18/491525 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058923 [patent_doc_number] => 11938116 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Treatments with nirogacestat [patent_app_type] => utility [patent_app_number] => 18/491283 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 26240 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 344 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18970319 [patent_doc_number] => 20240050411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => TREATMENTS WITH NIROGACESTAT [patent_app_type] => utility [patent_app_number] => 18/491379 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19026281 [patent_doc_number] => 11925620 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-12 [patent_title] => Treatments with nirogacestat [patent_app_type] => utility [patent_app_number] => 18/491225 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 26215 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 339 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19241018 [patent_doc_number] => 12011434 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Treatments with nirogacestat [patent_app_type] => utility [patent_app_number] => 18/491323 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 26239 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 345 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332468 [patent_doc_number] => 20240246898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/489240 [patent_app_country] => US [patent_app_date] => 2023-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995867 [patent_doc_number] => 11912694 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-27 [patent_title] => 2-(benzo[d]oxazol-2-yl)-N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)acetimidamide as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/484393 [patent_app_country] => US [patent_app_date] => 2023-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3999 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18484393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19135526 [patent_doc_number] => 11970456 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-30 [patent_title] => Synthesis of thiosemicarbazide analogue as inhibitor of tyrosinase, skin hyperpigmentation, and fruit and/or vegetable browning [patent_app_type] => utility [patent_app_number] => 18/371092 [patent_app_country] => US [patent_app_date] => 2023-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 3353 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18371092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19825268 [patent_doc_number] => 12246022 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-11 [patent_title] => Compositions and methods for treating, preventing or reversing age associated inflammation and disorders [patent_app_type] => utility [patent_app_number] => 18/470182 [patent_app_country] => US [patent_app_date] => 2023-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 118 [patent_no_of_words] => 43151 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18470182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921352 [patent_doc_number] => 20240024356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES [patent_app_type] => utility [patent_app_number] => 18/464965 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861801 [patent_doc_number] => 20230416236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) [patent_app_type] => utility [patent_app_number] => 18/460047 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18916686 [patent_doc_number] => 11878955 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-01-23 [patent_title] => 3,3',3''-nitrilotris(1-(naphthalen-2-yloxy)propan-2-ol) as an eco-friendly insecticidal agent against [patent_app_type] => utility [patent_app_number] => 18/457725 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2839 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18457725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995849 [patent_doc_number] => 11912676 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-27 [patent_title] => N'-[(4-chlorobenzoyl)oxy]-1,3-benzothiazole-2-carboximidamide as an antitumor and antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/239495 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3816 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18239495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19778448 [patent_doc_number] => 12227472 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Series of skin-whitening (lightening) compounds [patent_app_type] => utility [patent_app_number] => 18/238905 [patent_app_country] => US [patent_app_date] => 2023-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 13439 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19624058 [patent_doc_number] => 12162862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Beta-lactam derivatives for the treatment of diseases [patent_app_type] => utility [patent_app_number] => 18/237140 [patent_app_country] => US [patent_app_date] => 2023-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55416 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18237140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343535 [patent_doc_number] => 20240252498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => GAMMA POLYGLUTAMATED LOMETREXOL AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/237151 [patent_app_country] => US [patent_app_date] => 2023-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18237151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18785989 [patent_doc_number] => 20230373903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => CATIONIC LIPIDS AND TRANSFECTION METHODS [patent_app_type] => utility [patent_app_number] => 18/362789 [patent_app_country] => US [patent_app_date] => 2023-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18362789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19026280 [patent_doc_number] => 11925619 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Treatments with nirogacestat [patent_app_type] => utility [patent_app_number] => 18/361884 [patent_app_country] => US [patent_app_date] => 2023-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 26239 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216229 [patent_doc_number] => 20240180933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/358998 [patent_app_country] => US [patent_app_date] => 2023-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18358998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986313 [patent_doc_number] => 20240058282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB [patent_app_type] => utility [patent_app_number] => 18/357988 [patent_app_country] => US [patent_app_date] => 2023-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18357988 [rel_patent_id] =>[rel_patent_doc_number] =>)